Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases.
Study Goal
The researchers aimed to assess the prevalence and effects of a gluten-free diet (GFD) among patients with inflammatory bowel diseases (IBD), focusing on symptom improvement and adherence.
Results Summary
A substantial number of IBD patients had tried a GFD, with 65.6% reporting improved gastrointestinal symptoms and 38.3% experiencing fewer or less severe IBD flares. Excellent adherence to GFD was associated with significant improvement in fatigue.
Population
Patients with inflammatory bowel diseases (IBD) participating in the CCFA Partners longitudinal Internet-based cohort (n=1647).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
gluten-free diet (GFD) | decrease | gastrointestinal symptoms | patients with inflammatory bowel diseases (IBD) who attempted a GFD | 65.6% | described an improvement | #1 |
gluten-free diet (GFD) | decrease | IBD flares | patients with inflammatory bowel diseases (IBD) who attempted a GFD | 38.3% | reported fewer or less severe | #2 |
gluten-free diet (GFD) with excellent adherence | decrease | fatigue | patients with inflammatory bowel diseases (IBD) currently attempting a GFD | - | significant improvement | #3 |
BACKGROUND: Maintaining a gluten-free diet (GFD) without an underlying diagnosis of celiac disease has enjoyed widespread acceptance in the Unites States. METHODS: We performed a cross-sectional study using a GFD questionnaire in 1647 patients with inflammatory bowel diseases (IBD) participating in the CCFA Partners longitudinal Internet-based cohort. RESULTS: A diagnosis of celiac disease and non-celiac gluten sensitivity were reported by 10 (0.6%) and 81 (4.9%) respondents, respectively. Three hundred fourteen (19.1%) participants reported having previously tried a GFD and 135 (8.2%) reported current use of GFD. Overall 65.6% of all patients, who attempted a GFD, described an improvement of their gastrointestinal symptoms and 38.3% reported fewer or less severe IBD flares. In patients currently attempting a GFD, excellent adherence was associated with significant improvement of fatigue (P < 0.03). CONCLUSIONS: In this large group of patients with IBD, a substantial number had attempted a GFD, of whom the majority had some form of improvement in gastrointestinal symptoms. Testing a GFD in clinical practice in patients with significant intestinal symptoms, which are not solely explained by the degree of intestinal inflammation, has the potential to be a safe and highly efficient therapeutic approach. Further prospective studies into mechanisms of gluten sensitivity in IBD are warranted.